Evaxion AS

EVAX

Company Profile

  • Business description

    Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

  • Contact

    Dr. Neergaards Vej 5f
    Horsholm2970
    DNK

    T: +45 31246427

    E: [email protected]

    https://www.evaxion.ai

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    46

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,246.31105.69-1.27%
DAX 4026,266.46332.18-1.25%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,744.36137.19-1.26%
HKSE23,508.17245.67-1.03%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.590.000.00%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers